MicroPort NeuroScientific

MicroPort NeuroScientific FCF Yield

The Free Cash Flow Yield of MicroPort NeuroScientific (2172.HK) as of Oct 27, 2026 is 2.51 %. In the previous year, Free Cash Flow Yield was 3.81 % — a change of -34.15% (lower).

FCF Yield

2.51 %

YoY

-34.15%

Last updated:

Free Cash Flow Yield of MicroPort NeuroScientific is 2025 2.51 % . Free Cash Flow Yield of MicroPort NeuroScientific was 2024 3.81 % . It decreases by -34.15% lower compared to the previous year.

The MicroPort NeuroScientific FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
0.11 CNY
Jan 1, 2020
0.21 CNY
Jan 1, 2021
1.61 CNY
Jan 1, 2022
2.85 CNY
Jan 1, 2023
-0.79 CNY
Jan 1, 2024
3.81 CNY
Jan 1, 2025
2.51 CNY
The MicroPort NeuroScientific FCF Yield history
YEARFCF YieldYoY
2.51 %-34.15%
3.81 %-580.07%
-0.79 %-127.76%
2.85 %+76.87%
1.61 %+659.56%
0.21 %+98.97%
0.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroPort NeuroScientific Stock analysis

What does MicroPort NeuroScientific do? MicroPort NeuroTech Ltd. generates revenue through the research, development, manufacturing, and sales of neuro-interventional medical devices. Its main products include embolization coils, flow-diverting stents, and stent grafts, targeting three key areas of neurovascular diseases: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company serves domestic and overseas markets, with its products primarily used by hospitals and healthcare providers for treating brain diseases. The firm's focus on neurovascular disease solutions drives its commercial strategy. The company operates under the brand MicroPort NeuroTech Ltd., which is part of the broader MicroPort group. It targets healthcare institutions globally, particularly those specializing in neurovascular care. The firm's product portfolio addresses critical treatment needs in neurovascular conditions, aligning with the growing demand for advanced medical devices in stroke management. Revenue streams are derived from direct sales of its medical devices to hospitals and clinics. MicroPort NeuroTech Ltd. focuses on the domestic and overseas markets, with its products designed for specific neurovascular applications. The company's revenue model relies on the sale of embolization coils, flow-diverting stents, and stent grafts to healthcare providers. These products are essential for treating conditions like hemorrhagic stroke and acute ischemic stroke, which are major causes of neurological disability. The firm's strategy emphasizes innovation in neuro-interventional solutions to capture market share in both local and international segments. MicroPort NeuroScientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroPort NeuroScientific stock

Free Cash Flow Yield of MicroPort NeuroScientific is 2.51 % in 2025.

Free Cash Flow Yield of MicroPort NeuroScientific changed from 3.81 % to 2.51 %, representing a -34.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield MicroPort NeuroScientific since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's MicroPort NeuroScientific with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MicroPort NeuroScientific

All Key Metrics — MicroPort NeuroScientific